A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Pedro M. Folegatti, Kate Harrison, Lorena Preciado-Llanes, Fernando Ramos Lopez, Mustapha Bittaye, Young Chan Kim, Amy Flaxman, Duncan Bellamy, Rebecca Makinson, Jonathan Sheridan, Sasha R. Azar, Rafael Kroon Campos, Mark Tilley, Nguyen Tran, Daniel Jenkin, Ian Poulton, Alison Lawrie, Rachel Roberts, Eleanor Berrie, Shannan L. Rossi, Adrian Hill, Katie J. Ewer and Arturo Reyes-Sandoval ()
Additional contact information
Pedro M. Folegatti: University of Oxford
Kate Harrison: University of Oxford
Lorena Preciado-Llanes: University of Oxford
Fernando Ramos Lopez: University of Oxford
Mustapha Bittaye: University of Oxford
Young Chan Kim: University of Oxford
Amy Flaxman: University of Oxford
Duncan Bellamy: University of Oxford
Rebecca Makinson: University of Oxford
Jonathan Sheridan: University of Oxford
Sasha R. Azar: University of Texas Medical Branch
Rafael Kroon Campos: University of Texas Medical Branch
Mark Tilley: University of Oxford
Nguyen Tran: University of Oxford
Daniel Jenkin: University of Oxford
Ian Poulton: University of Oxford
Alison Lawrie: University of Oxford
Rachel Roberts: University of Oxford
Eleanor Berrie: University of Oxford
Shannan L. Rossi: University of Texas Medical Branch
Adrian Hill: University of Oxford
Katie J. Ewer: University of Oxford
Arturo Reyes-Sandoval: University of Oxford

Nature Communications, 2021, vol. 12, issue 1, 1-10

Abstract: Abstract Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein (Capsid, E3, E2, 6k and E1). 24 adult healthy volunteers aged 18–50 years, were recruited in a dose escalation, open-label, nonrandomized and uncontrolled phase 1 trial (registry NCT03590392). Participants received a single intramuscular injection of ChAdOx1 Chik at one of the three preestablished dosages and were followed-up for 6 months. The primary objective was to assess safety and tolerability of ChAdOx1 Chik. The secondary objective was to assess the humoral and cellular immunogenicity. ChAdOx1 Chik was safe at all doses tested with no serious adverse reactions reported. The vast majority of solicited adverse events were mild or moderate, and self-limiting in nature. A single dose induced IgG and T-cell responses against the CHIKV structural antigens. Broadly neutralizing antibodies against the four CHIKV lineages were found in all participants and as early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, tolerability and 100% PRNT50 seroconversion after a single dose.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-24906-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-24906-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-24906-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().